HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 277, Issue 17, 15035-15043, April 26, 2002

This Article Full Text Full Text (PDF) All Versions of this Article: 277/17/15035    most recent M112028200v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Deng, H. B. Articles by Simpkins, H. Search for Related Content PubMed PubMed Citation Articles by Deng, H. B. Articles by Simpkins, H. Social Bookmarking                      What's this?

Increased Expression of Dihydrodiol Dehydrogenase Induces Resistance to Cisplatin in Human Ovarian Carcinoma Cells^*

Hong Bing Deng, Hemant K. Parekh, K.-C. Chow^§, and Henry Simpkins^¶

From the  Department of Pathology and Laboratory Medicine, ^¶ Fels Institute of Cancer Research and Molecular Biology, Temple University School of Medicine, Philadelphia, Pennsylvania 19140 and the ^§ Department of Medical Research, China Medical College Hospital, 2 Yuh-Der Rd., Taichung, Taiwan 404, Republic of China

We employed cDNA microarrays to identify the differentially expressed genes in a cisplatin-sensitive parental (2008) human ovarian carcinoma cell line and its cisplatin-resistant variant (2008/C13*). Differential expression of five genes was found in the 2008/C13* cells, a result confirmed by semi-quantitative reverse transcription-PCR. The five genes were identified as fibroblast muscle-type tropomyosin and skeletal muscle-type tropomyosin, dihydrodiol dehydrogenase, apolipoprotein J and glucose-6-phosphate dehydrogenase variant-A. Treatment of the 2008 cells with cisplatin (at its IC₅₀ concentration of 2 µM) induced expression of these genes, as determined by semi-quantitative reverse transcription-PCR analysis using gene-specific primers. In contrast, treatment of the drug-resistant 2008/C13* cells with cisplatin (at its IC₅₀ concentration of 20 µM) did not lead to the induction of any of the aforementioned genes. Most importantly, constitutive overexpression of dihydrodiol dehydrogenase (but not the other genes) in the 2008 cells led to induction of cisplatin resistance, clearly indicating its role in the development of the resistance phenotype in the 2008/C13* cells. The development of cisplatin resistance in the transfected cells was associated with an increase in the dihydrodiol dehydrogenase enzyme activity. Although at present it is not clear how dihydrodiol dehydrogenase is involved in cisplatin resistance, the identification of this gene as a causal factor suggests the existence of a hitherto undefined pathway resulting in cisplatin resistance.

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				L. Zhang, J. J. Lee, H. Tang, Y.-H. Fan, L. Xiao, H. Ren, J. Kurie, R. C. Morice, W. K. Hong, and L. Mao Impact of Smoking Cessation on Global Gene Expression in the Bronchial Epithelium of Chronic Smokers Cancer Prevention Research, July 1, 2008; 1(2): 112 - 118. [Abstract] [Full Text] [PDF]

				H. Lou, S. Du, Q. Ji, and A. Stolz Induction of AKR1C2 by Phase II Inducers: Identification of a Distal Consensus Antioxidant Response Element Regulated by NRF2 Mol. Pharmacol., May 1, 2006; 69(5): 1662 - 1672. [Abstract] [Full Text] [PDF]

				G. Marverti, M. G. Monti, A. E. Pegg, D. E. McCloskey, S. Bettuzzi, A. Ligabue, A. Caporali, D. D'Arca, and M. S. Moruzzi Spermidine/spermine N1-acetyltransferase transient overexpression restores sensitivity of resistant human ovarian cancer cells to N1,N12-bis(ethyl)spermine and to cisplatin Carcinogenesis, October 1, 2005; 26(10): 1677 - 1686. [Abstract] [Full Text] [PDF]

				T. M. Penning AKR1B10: A New Diagnostic Marker of Non-Small Cell Lung Carcinoma in Smokers Clin. Cancer Res., March 1, 2005; 11(5): 1687 - 1690. [Full Text] [PDF]

				L. A. Wilson, H. Yamamoto, and G. Singh Role of the transcription factor Ets-1 in cisplatin resistance Mol. Cancer Ther., July 1, 2004; 3(7): 823 - 832. [Abstract] [Full Text] [PDF]

				V. Poindessous, F. Koeppel, E. Raymond, M. Comisso, S. J. Waters, and A. K. Larsen Marked Activity of Irofulven toward Human Carcinoma Cells: Comparison with Cisplatin and Ecteinascidin Clin. Cancer Res., July 1, 2003; 9(7): 2817 - 2825. [Abstract] [Full Text] [PDF]